| Revenue Growth | Total revenue $449,000; Grant revenue down $538,000; R&D revenue down $188,000. |
|---|---|
| Mgmt Confidence | Hedging on timelines; admitted adoption is taking longer than originally anticipated. |
| Demand Visibility | Increased sampling requests for transferrin; making to demand due to capital. |
| Order Book | Contractual $225,000 payment expected in Q4 from Ensigns commercial sale. |
| Margin Trends | Cost of revenue decreased 63% to $375,000 following lower grant activity. |
| Op. Leverage | Leveraging third-party distributors like IBT Bioservices to limit direct sales costs. |
| Vol vs Price | Growth driven by initial direct sales and partner-led commercialization milestones. |
| Segment Growth | Life Sciences recorded first direct sales; Food/Nutrition added second commercial product. |
| New Clients | Expanded collaboration with BrightBio and Strive Nutrition for dairy proteins. |
| Capex & Debt | Ended quarter with $6 million cash; $2.9 million raised in August. |
| Regulatory | Delayed 10-Q filing due to Microsoft Outlook issue; self-affirmed GRAS needed. |
| Commentary | Shifting focus to larger strategic partnerships to leverage partner capital and infrastructure. |
| New Launches | IBT Bioservices launched six research-use-only recombinant protein products. |
Growth
Q3 revenue fell 61% to $449,000; nine-month revenue flat at $2.5 million.
Outlook
Targeting 10 to 200 metric tons of Alpha-lactalbumin supply for Strive Nutrition.
Risks
Management pivoted on adoption delays, citing regulatory hurdles and customer workflow integration timelines.
The company's earnings call, NASDAQ: DYAI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Dyadic International Inc: key numbers
- Share price
- $0.3200Close, Nov 16
- Market cap
- $12.8M
- Shares outstanding
- 40.09MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dyadic International Inc
All →Dyadic International Q3 2026 Results: Net Loss of $1.36M, Loss Narrows
Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.
- Key figure
- Net loss $1.36M
Dyadic International Financial Results
Dyadic International reported Q3 2026 financial results, highlighting its first direct commercial protein sales and expanded OEM distribution through IBT Bioservices. The company reported a net loss of $1.5M on revenue of $0.7M as it shifts focus toward larger strategic partnerships and licensing arrangements for its C1 and Dapibus production platforms.
- Term
- Q3 2026
“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors.”
Joe Hazelton, President and Chief Operating Officer
“Looking ahead, we are placing greater emphasis on larger strategic partnerships and collaborations, licensing and supply arrangements, and other potential transactions involving our platforms, products, and commercial programs.”
Joe Hazelton, President and Chief Operating Officer
Dyadic International Nasdaq/NYSE Compliance Notice
Dyadic International received two deficiency notices from Nasdaq for failing to maintain a minimum bid price of $1.00 per share and a minimum Market Value of Listed Securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, until March 24, 2027, to regain compliance with both requirements.
- Counterparty
- The Nasdaq Stock Market LLC
- Term
- 180 days